Ozempic NAION Warning: FDA Adds Rare Eye Risk to Every GLP-1 Drug Label
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here is what the data show.
The FDA now requires all 12 GLP-1 drugs, including Ozempic, Wegovy and Mounjaro, to warn of NAION, a rare cause of sudden vision loss. Here is what the data show.
Mayo Clinic data from ObesityWeek 2026 show GLP-1 users with weakened hearts saw greater one-year gains in heart structure and function than matched non-users, with most benefits holding after adjusting…